*/ .cpi-spinner-loader { width: 60px; aspect ratio: 2; —_g: non-repeating radial-gradient(side closest to circle, #000 90%, #0000); background: var(–_g) 0% 50%, var(–_g) 50% 50%, var(–_g) 100% 50%;background size: calc(100%/3) 50%;animation: l3 1s infinite linear; } @keyframes l3 { 20% { background position: 0% 0%, 50% 50%, 100% 50% } 40% { background position: 0% 100%, 50% 0%, 100% 50% } 60% { Background position: 0% 50%, 50% 100%, 100% 0% 80% {Background position: 0% 50%, 50% 50%, 100% 100% } }
The U.S. Food and Drug Administration is creating a new regulatory framework for artificial intelligence and machine learning in medical software. This article argues that FDA’s evolving approach extends beyond compliance issues for technology developers. This is a market-shaping force that will change how healthcare providers purchase, deploy, and manage AI-enabled tools. The study examines four downstream impacts based on recent FDA guidance, academic research, and industry analysis.
…
This article is not available for IP address 93.127.192.203
please Verify your email address or join for access to premium content!
